Onyx gets fast track; Pervasis in partnership talks;

@FierceBiotech: Antisoma struggling to survive as another cancer drug flunks Ph3. Report | Follow @FierceBiotech

@JohnCFierce: Reuters says that Sanofi-Genz deal could be wrapped in a week or two. At long last... Story | Follow @JohnCFierce

> Editorial: Seeking middle ground for the FDA. Item

> Orexigen crashes after FDA demands pre-approval Contrave study. News 

> Onyx says that the FDA has provided fast-track status for carfilzomib, a promising multiple myeloma drug which has the potential to go on to become a blockbuster new cancer therapy. An application is expected in the middle of this year. Story

> Xconomy reports that Pervasis is in advanced talks with potential partners interested in Vascugel, a therapy designed to improve vascular access. Story

> After partly divesting DNage, Pharming says that the subsidiary will be shut down after failing to find new backers. Story

> Optivia Biotechnology and the FDA have signed a collaboration agreement to assess the effect of dietary supplements on key drug transporters. The goal of the collaboration is to identify potentially harmful drug-dietary supplement interactions, such as an interaction with acetaminophen and other drugs associated with liver toxicity. Release

And Finally... Dogs can sniff out bowel cancer in breath and stool samples, with a very high degree of accuracy--even in the early stages of the disease--reveals research published online in the journal Gut. Report